On April 9, 2024 Manhattan BioSolutions, Inc. ("Manhattan Bio"), an emerging biotechnology company developing new classes of precision biologics for the treatment of advanced cancers, reported a collaborative poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 in San Diego, California (Press release, Manhattan BioSolutions, APR 9, 2024, View Source [SID1234641936]). The poster, titled "A potent FGFR4-targeted antibody-drug conjugate therapy for patients with rhabdomyosarcoma and other cancers expressing FGFR4," highlights the promising preclinical efficacy of this innovative therapeutic approach. The research is a result of a collaboration between Manhattan Bio, the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH), and Binghamton University.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The lead investigator is Javed Khan, MD, Senior Investigator and Deputy Chief of the Genetics Branch at the NCI Center for Cancer Research. The study utilized a highly specific monoclonal antibody that targets FGFR4, a receptor overexpressed in various cancers, including rhabdomyosarcoma (RMS). The antibody was conjugated to the cytotoxic MMAE payload through a protease-cleavable valine-citrulline linker, generating a potent FGFR4-targeted ADC. This work builds on an earlier collaboration agreement between Manhattan Bio, the NCI, and Binghamton University announced in 2023.
"We are thrilled to share the compelling preclinical data generated through our ongoing collaboration with the NCI and Binghamton University," said Dr. Borys Shor, CEO of Manhattan Bio. "While this proof-of-concept study utilized a standard linker-payload system, we are excited to continue our work with cutting-edge topoisomerase 1 inhibitor warheads currently being developed at Manhattan Bio. We believe that by combining the highly selective FGFR4 antibody with our proprietary linker-payload technologies, we can further enhance the therapeutic potential of this ADC for pediatric patients with RMS and for patients with other types of tumors."